Second-Season RSV Immunization Worked for Eligible Children
(MedPage Today) -- WASHINGTON -- Real-world data backed the effectiveness of second-season nirsevimab (Beyfortus) immunizations against hospitalizations for children at high risk for severe respiratory syncytial virus (RSV) illness. In the case...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.